Back
Full-text
Journal article

Towards a cancer mission in Horizon Europe: recommendations.

  • Berns A The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Ringborg U European Academy of Cancer Sciences, Stockholm, Sweden.
  • Celis JE European Academy of Cancer Sciences, Stockholm, Sweden.
  • Heitor M Ministry for Science, Technology and Higher Education, Lisbon, Portugal.
  • Aaronson NK The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Abou-Zeid N Fondation ARC pour la recherché sur le cancer, Villejuif, France.
  • Adami HO Karolinska Institutet, Stockholm, Sweden.
  • Apostolidis K European Cancer Patient Coalition, Brussels, Belgium.
  • Baumann M European Academy of Cancer Sciences, Stockholm, Sweden.
  • Bardelli A The European Association for Cancer Research, Nottingham, UK.
  • Bernards R The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Brandberg Y Karolinska Institutet, Stockholm, Sweden.
  • Caldas C European Academy of Cancer Sciences, Stockholm, Sweden.
  • Calvo F Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.
  • Dive C The European Association for Cancer Research, Nottingham, UK.
  • Eggert A Charite-Universitatsmedizin, Berlin, Germany.
  • Eggermont A European Academy of Cancer Sciences, Stockholm, Sweden.
  • Espina C International Agency for Research on Cancer (IARC/WHO), Lyon, France.
  • Falkenburg F Dutch Cancer Society, Amsterdam, the Netherlands.
  • Foucaud J French National Cancer Institute (INCa), Boulogne Billancourt, France.
  • Hanahan D Swiss Institute for Experimental Cancer Research (ISREC), Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.
  • Helbig U German Cancer Aid, Bonn, Germany.
  • Jönsson B Stockholm School of Economics, Stockholm, Sweden.
  • Kalager M Institute of Health and Society, University of Oslo, Oslo, Norway.
  • Karjalainen S Association of European Cancer Leagues (ECL), Brussels, Belgium.
  • Kásler M Ministry of Human Resources, Budapest, Hungary.
  • Kearns P SIOPE Head Office, Brussels, Belgium.
  • Kärre K The Swedish Cancer Society, Stockholm, Sweden.
  • Lacombe D EORTC Headquarters, Brussels, Belgium.
  • de Lorenzo F European Cancer Patient Coalition, Brussels, Belgium.
  • Meunier F Federation of European Academies of Medicine, Brussels, Belgium.
  • Nettekoven G German Cancer Aid, Bonn, Germany.
  • Oberst S Cancer Research UK Cambridge Centre, Cambridge, UK.
  • Nagy P Organisation of European Cancer Institutes (OECI), Brussels, Belgium.
  • Philip T Organisation of European Cancer Institutes (OECI), Brussels, Belgium.
  • Price R The European Cancer Organisation (ECCO), Brussels, Belgium.
  • Schüz J International Agency for Research on Cancer (IARC/WHO), Lyon, France.
  • Solary E Fondation ARC pour la recherché sur le cancer, Villejuif, France.
  • Strang P Karolinska Institutet, Stockholm, Sweden.
  • Tabernero J Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Voest E The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Show more…
  • 2020-08-05
Published in:
  • Molecular oncology. - 2020
European healthcare systems
cancer mission
cancer research/care/prevention continuum
comprehensive cancer centres
patient empowerment
science policy
English A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research-care-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence-based advice.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/37696
Statistics
Document views: 93 File downloads:
  • Full-text: 0